Published on : 03 Dec 2025, 5:49 pm 4 min read

The Delhi High Court on Tuesday dismissed Novo Nordisk's application to restrain Dr. Reddy's Laboratories Limited and OneSource Specialty Pharma Limited from manufacturing and exporting diabetes and weight management drug Semaglutide [Novo Nordisk v. Dr Reddy's].

Semaglutide is marketed under brand names like Ozempic, Wegovy and Rybelsus by Novo Nordisk.

Justice Manmeet Pritam Singh Arora found that Dr. Reddy's (defendant) raised a credible challenge to the validity of the suit patent by Novo Nordisk on grounds of prior claiming and obviousness.

Dr. Reddy's was permitted to continue manufacturing the drug in India for export to non-patented territories, subject to maintaining accounts.

"Since the Plaintiff (Novo Nordisk) is no

See Full Page